Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: Is it time for a step forward?

Archives of Gynecology and Obstetrics

Volumn 288, Issue 1, 2013, Pages 167-172

  Azzam, Amal Z ^a   Hashad, Doaa I ^a   Kamel, Nahla A F ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Benign ovarian tumors; CA125; HE4; Ovarian cancer; ROC curve

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; ARTICLE; CANCER DIAGNOSIS; CHEMILUMINESCENCE IMMUNOASSAY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PELVIS ULTRASONOGRAPHY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; AREA UNDER CURVE; CA-125 ANTIGEN; CARCINOMA; CASE-CONTROL STUDIES; CYSTADENOMA, SEROUS; DOUBLE-BLIND METHOD; ENDOMETRIOSIS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEINS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84879409530     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2722-2     Document Type: Article

References (33)

1. Moore R, Brown A, Miller M et al (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108:402-408 (Pubitemid 351174295)
2. Escudero J, Auge J, Filella X et al (2011) Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and non malignant diseases. Clin Chem 57:1534-1544
3. Suh K, Park S, Castro A et al (2010) Ovarian cancer biomarkers for molecular biosensors and translation medicine. Expert Rev Mol Diag 10:1069-1083
4. Hartge P, Whittemore S, Itnyre J et al (1994) Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol 84(5):760-764 (Pubitemid 24329840)
5. Kumar V, Fausto N, Abbas A (2005) Robbins & Cotran Pathologic basis of diseases, 7th edn. Saunders, Philadelphia
6. Banks E (2000) The epidemiology of ovarian cancer. In: Bartlett JMS (ed) Ovarian cancer: methods and protocols. Humana Press, Totowa
7. Bast RC (2003) Status of tumor markers in ovarian cancer screening. J Clin Oncol 21(10):200S-205S
8. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics 2009. CA Cancer J Clin 59:225-249
9. Heitz A, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. Int J Gynecol Obstet 95:S161-S192 (Pubitemid 44854933)
10. Huhtinen K, Suvitie P, Hissa J et al (2009) Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts. Br J Cancer 100:1315-1319
11. Rosen D, Atkinson J, Yu Y et al (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267-277 (Pubitemid 41502830)
12. Sturgeon C, Duffy M, Stenman U et al (2008) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancer. Clin Chem 54:e11-e79 (Pubitemid 352777353)
13. How S, Liam C, Jamalludin A (2006) Serum cancer antigen 125 in patients with pleural effusions. Med J Malaysia 61:558-563 (Pubitemid 46569502)
14. Havrilesky L, Whitehead C, Rubatt J et al (2008) Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrences. Gynecol Oncol 110:374-382
15. Gao L, Cheng GHY, Dong L et al (2011) The role of HE4 in ovarian cancer: inhibiting tumor cell proliferation and metastasis. J Int Med Res 39:1645-1660
16. Drapkin R, Von-Horsten HH, Lin Y et al (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometroid ovarian carcinomas. Cancer Res 65:2162-2169 (Pubitemid 40490123)
17. Chen L (ed) (2010) Diagnostic Gynecologic and Obstetric Pathology, 2nd edn.: People's Military Medical Press, Beijing, pp 268-394
18. Kaku T, Ogawa S, Kawano Y et al (2003) Histological classification of ovarian cancer. Med Electron Microsc 36:9-17 (Pubitemid 36504385)
19. Benedet JL, Bender H, Jones H et al (2000) FIGO staging classification and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynecol Obstet 70:209-262
20. Terry K, Skates S, Mok S et al (2004) Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20:53-70 (Pubitemid 39149915)
21. Dutta S, Wang F, Fishman D (2010) The dire need to develop a clinically validated screening method for the detection of early stage ovarian cancer. Biomark Med 4:437-439
22. Badgwell D, Bast R (2007) Early detection of ovarian cancer. Dis Markers 23(5-6):397-410 (Pubitemid 350171267)
23. Moore R, Mc-Meekin D, Brown A et al (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40-46
24. Molina R, Filella X, Bruix J et al (1991) Cancer antigen 125 in serum and ascitic fluid for patients with liver disease. Clin Chem 37:1379-1383 (Pubitemid 21925975)
25. Nolen B, Velikokhatnaya L, Marrangoni A et al (2010) Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117:440-445
26. Moore R, Brown A, Miller M et al (2008) Utility of a novel serum tumor biomarker HE4 in patients with endometroid adenocarcinoma of the uterus. Gynecol Oncol 110:196-201
27. Yamashita S, Heagerty K, Hashimoto T et al (2011) Prognostic significance of HE4 in pulmonary adenocarcinoma. Tumor boil 32:265-271
28. Montagnana M, Lippi G, Ruzzenete O et al (2009) The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 23:331-335
29. Hellstrom I, Raycraft J, Hayden-ledbetter M et al (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63:3695-3760
30. Hellstrom I, Hellstrom K (2008) SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol 622:15-21
31. Ayhan A, Guven S, Guven E et al (2007) Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand 86:484-490 (Pubitemid 46747698)
32. Yin B, Lloyd K (2001) Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276:27371-27375
33. Abdel-Azeez H, Labib H, Sharaf S et al (2010) HE4 and mesothelin: novel biomarker of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 11(1):111-116